Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Halozyme and Roche team up assessing drug combo in range of cancers

Published 11/10/2016, 10:00 AM
Halozyme and Roche team up assessing drug combo in range of cancers
HALO
-
RHHBY
-
  • Halozyme Therapeutics (HALO +11.9%) and Roche's (OTCQX:RHHBY -1.3%) Genentech will collaborate in clinical trials assessing the combination of Tecentriq (atezolizumab) and Halozyme's PEGPH20 in up to eight tumor types beginning next year.
  • The first study will be an open-label Phase 1b/2 led by Genentech that will evaluate the combination in six tumor types, with an initial focus on gastrointestinal malignancies, including pancreatic and gastric cancers, some of whom will have high levels of hyaluronan (HA). Halozyme's role will be supplying product.
  • Halozyme will lead the second study, an open-label Phase 1b assessing the combination along with chemo in patients with advanced/metastatic biliary and gallbladder cancers. Only patients with high HA levels will be enrolled.
  • PEGPH20 is an investigational drug administered intravenously that temporarily degrades HA, a chain of natural sugars that builds up around cancer cells inhibiting the effectiveness of cancer-killing therapies.
  • Atezolizumab is a PD-L1 antagonist that is designed to block inhibitory T-cell checkpoints thereby allowing cytotoxic T cells to reach the tumor.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.